Novel Treatment Modalities


The Collaborative Learning Exchange series on ‘Novel Treatment Modalities’ supports and engages hematologists, physician assistants, and nurse practitioners who prescribe therapies for individuals with hemophilia A and B.

What to Expect:
The Collaborative Learning Exchange series on ‘Novel Treatment Modalities’ will comprise several events to be delivered in 2022. These events will be held as live virtual interactive sessions.

Each workshop will include:

  • An informational overview of the topic,
  • Interactive breakout rooms to review the findings and/or discuss a pertinent case study,
  • Large group reconvening to summarize findings, and
  • Discussion of lessons learned.

Following each session, a resource flyer will be shared that supports the learnings from the event.

With several new treatments on the horizon, patients and healthcare providers need to prepare for how each of these novel treatments has the potential to impact current therapeutic management of hemophilia. Along with gene therapy products, several additional types of emerging “non-factor” therapeutics (RNA interference (RNAi), and anti-tissue factor pathway inhibitor (anti-TFPI) treatments hold promise. While these new therapeutics are still in various stages of clinical development, many prescribers may not fully understand the science and clinical evidence underpinning these novel therapies.  

Healthcare providers and particularly medical prescribers, need to remain aware of these therapeutic developments to be adequately prepared to discuss the possible risks and benefits with their patients. NHF, along with a group of key providers, has developed this collaborative learning exchange series to create new opportunities for prescribers to freely discuss amongst their peers, how novel therapies and novel non-factor therapies might impact current treatment decision-making and management for hemophilia A and B or in specific patient scenarios.    

Target Audience:
These activities are intended for hematologists, physician assistants, and nurse practitioners who regularly prescribe therapies for individuals living with hemophilia A and B.

The first Collaborative Learning Exchange activity, "Understanding Mechanisms of Action and Utility of Novel Treatments for Hemophilia A and B," was held live on April 6, 2022.

The second activity “Shared Decision Making in the Age of Novel Technologies for Hemophilia” was held live on May 5, 2022.

The third activity “Managing Complex Cases with Novel Non-Factor Therapies" was held live on June 9, 2022.

The fourth activity "Navigating Reimbursement for Patients on Non-Factor Therapy” was held live on July 12, 2022.



Novel Treatment Modalities - jointly accredited provider logoIn support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and National Hemophilia Foundation. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

These activities will provide accredited continuing education credits for physicians, physician assistants, and nurse practitioners.


National Hemophilia Foundation logo - no shadow University of Nebraska Medical Center logo